Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
04:03am, Saturday, 07'th Sep 2024
STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is signif
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
08:00am, Tuesday, 03'rd Sep 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
09:26am, Wednesday, 07'th Aug 2024
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.69 per share a year ago.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Tuesday, 16'th Jul 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Tuesday, 18'th Jun 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
12:10pm, Friday, 14'th Jun 2024
Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosom
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
04:30pm, Monday, 03'rd Jun 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Friday, 17'th May 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
09:06am, Monday, 06'th May 2024
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.53 per share a year ago.
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
07:00am, Monday, 06'th May 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
11:07am, Thursday, 25'th Apr 2024
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
08:00am, Wednesday, 17'th Apr 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
04:30pm, Thursday, 04'th Apr 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
11:40pm, Wednesday, 27'th Mar 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
09:51am, Wednesday, 27'th Mar 2024
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
